BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. The Company is developing prescription products through its proprietary HyantX™ delivery system for dermatology indications. BioPharmX has two lead products in development, BPX-04 for the treatment of papulopustular rosacea and BPX-01 for the treatment of acne vulgaris.